Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company based in Sweden, specializing in the development of innovative therapies targeting severe respiratory and fibrotic diseases, particularly through angiotensin II type 2 receptor agonists (ATRAGs). Its lead candidate, Buloxibutid (C21), is a first-in-class oral small molecule ATRAG in Phase 2b clinical trials for idiopathic pulmonary fibrosis (IPF), with Orphan Drug and Fast Track designations from the FDA, and under investigation for pulmonary arterial hypertension. The company also advances Almee, an investigational digital therapeutic medical device based on cognitive behavioral therapy, which has completed Phase III trials and received FDA Breakthrough Device Designation to mitigate the psychological effects of pulmonary fibrosis. Vicore collaborates with partners like Emeriti Bio AB, HaLaCore Pharma AB, and Alex Therapeutics AB to expand its pipeline, including follow-on ATRAG molecules and digital apps for interstitial lung diseases. Founded in 2000 and headquartered in Stockholm with 29 employees, Vicore Pharma Holding AB plays a key role in the biotechnology sector, focusing on disease-modifying treatments in healthcare.
kr 1.03
+kr 0.00 (+0.39%)
EOD Jun 26, 2026 · Twelve Data
The business is unprofitable at the operating level (-11905.82% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 96.5% YoY. Margins deteriorated 11731.7pp alongside, both lines moving the wrong way.
ROIC dropped from -18.98% to -32.27%, capital efficiency is deteriorating. Negative free cash flow of -kr 376M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 4M
▼ -96.5% YoY
Net Income (TTM)
-kr 475M
▼ -183.1% YoY
Op. Margin
-13800.54%
▼ -11731.7pp YoY
ROIC
-32.27%
▼ -13.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 407M
▼ -127.8% YoY
Op. Cash Flow (TTM)
-kr 423M
▼ -127.8% YoY
Net Debt
-kr 1.17B
Net Cash Position
Cash & Equiv.
kr 1.17B
Continue Research
Vicore Pharma Holding AB (VICO.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Vicore Pharma Holding AB scores 10/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Vicore Pharma Holding AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -13,800.5% operating margin and a -32.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh VICO.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.